Navigation Links
Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
Date:4/18/2013

HUNTSVILLE, Ala., April 18, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development based upon poly(oxazoline) - POZ, announced today that the company has entered into a definitive agreement with Woodside Capital Partners retaining them as the Company's advisor and investment bank. The details of the agreement were not disclosed.

"We are very pleased to announce that Serina Therapeutics has reached an agreement to have Woodside Capital Partners serve as our advisor and investment bank. Woodside Capital and its elite group of partners and life science advisors have a remarkable track record of helping to create shareholder value in promising biotechnology companies," said Randall Moreadith , MD, PhD, President and Chief Executive Officer of Serina. "Now that we are beginning to move our first clinical candidate toward Phase I in early 2014, and have signed an alliance with a large pharmaceutical partner for development of a POZ-therapeutic, we felt it was time to bring in an expert in doing deals across a wide range of companies in the pharmaceutical industry. We think Woodside Partners fills that need exceptionally well."

"Woodside Capital looks forward to working with the seasoned management team and board at Serina to complete additional transactions with selected pharmaceutical partners," said John Selig , Managing Director and co-head of Woodside Capital's Life Sciences Group. "We believe Serina's POZ technology has the potential to significantly improve the product profile of a large number of molecules across therapeutic areas."

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel p
'/>"/>

SOURCE Serina Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... developing better, faster and affordable treatments for tuberculosis (TB), ... Senior Vice President, Market Access. Ms. Robertson joins the ... the company,s business in Sub-Saharan Africa and ... will oversee the TB Alliance,s efforts to ensure beneficial ...
Breaking Medicine Technology:Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2genae Opens Offices in London 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
... SAN ANTONIO, July 12, 2011 Sevocity, the ... that Sevocity v11.1 has achieved full certification through ... and is a CCHIT Certified® 2011 Ambulatory EHR. ... usability rating, the highest level awarded by CCHIT. ...
... Surgical Care Affiliates (SCA), a national leader in ... and surgery departments, announced today it has entered into ... subsidiary of Suburban Hospital Healthcare System, Inc., a member ... in the Bethesda and Montgomery County areas. ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2Surgical Care Affiliates Announces Agreement With Suburban Outpatient Surgery Center 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... used birth control pills containing high-dose estrogen and a ... cancer, whereas women using some other formulations did not, ... a journal of the American Association for Cancer Research. ... contraceptives [birth control pills] in the past year is ... never or former oral contraceptive use, and that this ...
(Date:7/31/2014)... 2014 Developer Jamestown, L.P., has been ... Ponce City Market project in Atlanta’s Old Fourth Ward, ... Company building into best-in-class office, housing, and retail spaces. ... experience with their construction webcam service to assess how ... a construction camera for monitoring and documentation ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars , opened ... Horn Road in Lake Leelanau. Joining the Northern Loop of ... the 25th winery along the trail. The winery will participate ... making its trail event debut during the Harvest Stompede on ... and Faye Mathia opened the boutique winery in the former ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... 28 Dr. Jeffrey Cummings, Medical,Director of The ... the prestigious Ronald and Nancy Reagan Research Award ... themselves to, discovering new,treatments and methods of care ... In his speech of acceptance at the annual ...
... finds molecule boosted cells eliminating colitis, Crohn,s symptoms , , ... by intestinal bacteria can eliminate symptoms of inflammatory bowel ... includes Crohn,s disease and ulcerative colitis. , It ... and other mammals contain about 1,000 different species of ...
... of Pennsylvania School of Medicine have shown how Argos, ... binding growth factors that promote the progression of cancer. ... new drug designs for inhibiting cancer. The study appeared ... Many types of tumors grow because of over-expression of ...
... 300-Page Book, with Foreword by FDA,s Janet Woodcock, ... WASHINGTON, May 28 Now that the Food ... the safe use of,pharmaceuticals, drug manufacturers can be ... their marketing on,existing pharmaceuticals., To help pharmaceutical ...
... DRAXIS Health Inc. ("DRAXIS"),(TSX: DAX) (NASDAQ: DRAX ) ... all of DRAXIS, common shares have been acquired by,an ... common share. As a result, DRAXIS common stock is ... on the Toronto Stock Exchange at,market close on Thursday, ...
... engineer. As a youngster, she had a fascination with ... Today, Sullivan, an assistant professor of chemical engineering at ... applying her knowledge and talents to an area critical ... drugs and gene therapies to diseased and damaged cells ...
Cached Medicine News:Health News:Gut Bacteria Fights Inflammatory Bowel Disease 2Health News:Fruit fly protein acts as decoy to capture tumor growth factors, find Penn researchers 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:DRAXIS Announces Completion of Sale to Jubilant 2Health News:DRAXIS Announces Completion of Sale to Jubilant 3Health News:DRAXIS Announces Completion of Sale to Jubilant 4Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 2Health News:Sullivan wins NSF Career Award for research on therapeutic drug carriers 3
Features soft, low friction sheath that extends beyond the tip....
Designed to retain the desired curve during oral intubation....
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box....
Disposable Aluminum Satin Finish E/T Stylette, Adult 16, 25/box....
Medicine Products: